Market Closed -
Nasdaq
21:00:00 07/05/2024 BST
|
5-day change
|
1st Jan Change
|
66.72
USD
|
-0.95%
|
|
+1.09%
|
+21.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
733
|
348.4
|
771.5
|
655.9
|
1,052
|
1,400
|
-
|
-
|
Enterprise Value (EV)
1 |
733
|
348.4
|
771.5
|
655.9
|
1,052
|
1,400
|
1,400
|
1,400
|
P/E ratio
|
123
x
|
-15.4
x
|
-13.6
x
|
-13.2
x
|
64.9
x
|
51.5
x
|
32.4
x
|
20.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.55
x
|
1.67
x
|
3.57
x
|
2.07
x
|
2.16
x
|
2.62
x
|
2.43
x
|
2.3
x
|
EV / Revenue
|
3.55
x
|
1.67
x
|
3.57
x
|
2.07
x
|
2.16
x
|
2.62
x
|
2.43
x
|
2.3
x
|
EV / EBITDA
|
8.81
x
|
5.19
x
|
11.9
x
|
11.7
x
|
7.86
x
|
10
x
|
8.86
x
|
8.16
x
|
EV / FCF
|
-
|
-
|
1,008
x
|
-16.4
x
|
9.56
x
|
13.1
x
|
13.3
x
|
11.5
x
|
FCF Yield
|
-
|
-
|
0.1%
|
-6.11%
|
10.5%
|
7.66%
|
7.53%
|
8.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,886
|
11,996
|
16,742
|
16,304
|
19,083
|
20,980
|
-
|
-
|
Reference price
2 |
61.67
|
29.04
|
46.08
|
40.23
|
55.14
|
66.72
|
66.72
|
66.72
|
Announcement Date
|
27/02/20
|
09/03/21
|
15/03/22
|
09/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
206.5
|
208.5
|
216.1
|
316.4
|
486.8
|
535.1
|
575.9
|
609.3
|
EBITDA
1 |
83.16
|
67.12
|
64.84
|
55.86
|
133.8
|
140
|
158
|
171.5
|
EBIT
1 |
16.35
|
-16.02
|
-39.79
|
-35.28
|
46.97
|
51.6
|
63.46
|
74.4
|
Operating Margin
|
7.92%
|
-7.68%
|
-18.41%
|
-11.15%
|
9.65%
|
9.64%
|
11.02%
|
12.21%
|
Earnings before Tax (EBT)
1 |
3.157
|
-25.96
|
-56.06
|
-62.66
|
19.87
|
29.16
|
43.76
|
66.4
|
Net income
1 |
6.094
|
-22.55
|
-42.79
|
-49.52
|
17.15
|
23.16
|
34.82
|
53.1
|
Net margin
|
2.95%
|
-10.82%
|
-19.8%
|
-15.65%
|
3.52%
|
4.33%
|
6.05%
|
8.71%
|
EPS
2 |
0.5000
|
-1.880
|
-3.400
|
-3.050
|
0.8500
|
1.297
|
2.060
|
3.295
|
Free Cash Flow
1 |
-
|
-
|
0.765
|
-40.08
|
110.1
|
107.2
|
105.4
|
121.8
|
FCF margin
|
-
|
-
|
0.35%
|
-12.67%
|
22.61%
|
20.04%
|
18.31%
|
19.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
1.18%
|
-
|
82.27%
|
76.57%
|
66.74%
|
71%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
641.78%
|
462.96%
|
302.81%
|
229.38%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
09/03/21
|
15/03/22
|
09/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
52.06
|
60.93
|
64.48
|
73.86
|
83.82
|
94.23
|
106.8
|
116.5
|
131.8
|
131.7
|
126
|
131.1
|
136.8
|
141.2
|
134.8
|
EBITDA
1 |
16.64
|
16.2
|
4.273
|
9.861
|
19.55
|
23.33
|
33.01
|
34.12
|
36.48
|
30.2
|
31.08
|
33.51
|
36.91
|
38.57
|
37.78
|
EBIT
1 |
-3.562
|
-23.72
|
-19.2
|
-12.91
|
-4.995
|
1.82
|
9.895
|
12.4
|
17.95
|
6.726
|
9.657
|
11.72
|
14.35
|
15.87
|
16.31
|
Operating Margin
|
-6.84%
|
-38.94%
|
-29.77%
|
-17.48%
|
-5.96%
|
1.93%
|
9.27%
|
10.64%
|
13.61%
|
5.11%
|
7.66%
|
8.94%
|
10.49%
|
11.24%
|
12.1%
|
Earnings before Tax (EBT)
1 |
-7.13
|
-30.85
|
-25.9
|
-18.82
|
-12.22
|
-5.728
|
2.165
|
5.249
|
11.51
|
0.947
|
3.884
|
6.098
|
8.831
|
10.44
|
10.31
|
Net income
1 |
-4.447
|
-24.33
|
-20.54
|
-15.33
|
-9.006
|
-4.65
|
1.033
|
5.838
|
9.534
|
0.749
|
3.034
|
4.814
|
6.99
|
8.272
|
8.142
|
Net margin
|
-8.54%
|
-39.93%
|
-31.85%
|
-20.76%
|
-10.74%
|
-4.93%
|
0.97%
|
5.01%
|
7.23%
|
0.57%
|
2.41%
|
3.67%
|
5.11%
|
5.86%
|
6.04%
|
EPS
2 |
-0.3700
|
-1.720
|
-1.270
|
-0.9400
|
-0.5500
|
-0.2800
|
0.0600
|
0.2900
|
0.4500
|
0.0400
|
0.1467
|
0.2567
|
0.4100
|
0.4900
|
0.3900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/11/21
|
15/03/22
|
10/05/22
|
08/08/22
|
09/11/22
|
09/03/23
|
08/05/23
|
09/08/23
|
08/11/23
|
29/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
0.77
|
-40.1
|
110
|
107
|
105
|
122
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
6.64
|
6.14
|
2.56
|
8.88
|
8.87
|
9.6
|
9.7
|
12.7
|
Capex / Sales
|
3.21%
|
2.94%
|
1.18%
|
2.81%
|
1.82%
|
1.79%
|
1.68%
|
2.08%
|
Announcement Date
|
27/02/20
|
09/03/21
|
15/03/22
|
09/03/23
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
66.72
USD Average target price
79.8
USD Spread / Average Target +19.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +21.00% | 1.4B | | +33.43% | 700B | | -5.12% | 358B | | +19.59% | 330B | | +4.89% | 287B | | +15.85% | 236B | | +6.60% | 202B | | -9.28% | 197B | | +4.26% | 161B | | -3.54% | 157B |
Other Pharmaceuticals
|